<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04612699</url>
  </required_header>
  <id_info>
    <org_study_id>ZGJAK010</org_study_id>
    <nct_id>NCT04612699</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis</brief_title>
  <acronym>PSO</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Jaktinib in Patients With Moderate-to-Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is study designed to investigate the efficacy and safety of Jaktinib in the treatment of&#xD;
      participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis&#xD;
      Area and Severity Index (PASI) score and routine safety assessments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Psoriasis Area and Severity Index Score ≥75% (PASI 75) Improvement (Efficacy of Jaktinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])</measure>
    <time_frame>Week 12</time_frame>
    <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema (redness), and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Jaktinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])</measure>
    <time_frame>Week 8、12、16、20、24</time_frame>
    <description>The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Moderate-to-Severe Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Jaktinib 50mg Bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Jaktinib 50mg Bid+ Placebo 50mg Bid+ Placebo 75mg Bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Jaktinib 75mg Bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Jaktinib 75mg Bid+ Placebo 50mg*2 Bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Jaktinib 100mg Bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Jaktinib 50mg*2 Bid+ Placebo 75mg Bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 50mg*2 Bid+ Placebo 75mg Bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jaktinib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Jaktinib 100mg Bid</arm_group_label>
    <arm_group_label>Jaktinib 50mg Bid</arm_group_label>
    <arm_group_label>Jaktinib 75mg Bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Jaktinib 100mg Bid</arm_group_label>
    <arm_group_label>Jaktinib 50mg Bid</arm_group_label>
    <arm_group_label>Jaktinib 75mg Bid</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18~65 years old (including lower limit), no gender limit；&#xD;
&#xD;
          -  You must have active chronic plaque psoriasis for at least 6 months prior to entry&#xD;
             into the study；&#xD;
&#xD;
          -  You must have active plaque psoriasis covering at least 10% body surface area； You&#xD;
             must have Psoriasis Area and Severity Index (PASI) score of at least 12；You must have&#xD;
             Static Physician's Global Assessment (sPGA) score of at least 3；&#xD;
&#xD;
          -  The patient can communicate well with the investigator and follow the research and&#xD;
             follow-up procedures；&#xD;
&#xD;
          -  Understand and voluntarily sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  You must not have prior treatment with an oral Janus kinase (JAK) inhibitor；&#xD;
&#xD;
          -  You must not have received a phototherapy within 4 weeks prior to entry into the&#xD;
             study；&#xD;
&#xD;
          -  You must not have a history of active hepatitis B, hepatitis C, or human&#xD;
             immunodeficiency virus (HIV)；&#xD;
&#xD;
          -  You must not have a history of chronic alcohol abuse or intravenous (IV) drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xinghua Gao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of China Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinghua Gao, PhD</last_name>
    <phone>+86-024-83282524</phone>
    <email>gaobarry@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

